Assertio Announces Q3 EPS of 11 Cents Compared to (3 Cents) Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy ASRT?
Q3 Financial Performance: The company reported Q3 revenue of $49.46 million, significantly exceeding the consensus estimate of $27.02 million.
Future Guidance: CEO Mark Reisenauer expressed confidence in achieving the full-year 2025 guidance based on the strong financial results and ongoing integration efforts.
Operational Integration: Key integration efforts are underway to consolidate operations and align products, including Rolvedon, under Assertio Specialty Pharmaceuticals for improved efficiency and recognition.
Strategic Positioning: The company boasts a solid balance sheet and potential in key assets, positioning it well for future growth and strategic developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.770
Low
35.00
Averages
40.00
High
45.00
Current: 11.770
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Assertio Holdings to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Assertio Holdings will announce its fourth quarter and full year 2025 financial results on March 16, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings release, management will host a live webcast of the earnings call at 4:30 p.m. Eastern Time, providing investors with a direct opportunity to engage with management and enhance investor confidence.
- Access Information: Investors can visit Assertio's investor relations website to access the live webcast, conference call details, and other materials, ensuring they connect at least 10 minutes prior to the call for any necessary software downloads.
- Telephone Access Option: For those wishing to join by phone only, investors can dial +1 (646) 307-1963 and use call ID 3278948, ensuring flexibility in participation methods to meet investor needs.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Assertio Holdings Regains Nasdaq Compliance with Minimum Bid Price Rule
- Compliance Regained: Assertio Holdings announced that as of January 12, 2026, it has successfully regained compliance with Nasdaq listing requirements by maintaining a minimum bid price of $1.00 per share for ten consecutive days, marking a significant achievement in capital allocation flexibility.
- Successful Reverse Split: The company effectively increased its stock price through a reverse stock split completed in December 2025, ensuring compliance restoration efficiently, which not only boosts market confidence but also provides greater flexibility for future capital operations.
- CEO Statement: CEO Mark Reisenauer expressed satisfaction with the regained compliance, emphasizing that this achievement lays a foundation for the company's future growth and demonstrates Assertio's ongoing competitiveness in the pharmaceutical market.
- Company Background: Assertio is a pharmaceutical company focused on oncology, neurology, and pain management, dedicated to offering differentiated products designed to meet patient needs, and will continue to drive innovation to support patient health.
See More
Assertio Reports Positive Results for Same-Day Dosing of Rolvedon in Clinical Trial
- Clinical Trial Success: Assertio's Rolvedon demonstrated efficacy and safety comparable to next-day dosing in a clinical trial, indicating its potential for improving patient treatment experiences in early-stage breast cancer.
- Patient Participation: Conducted across 13 sites in the U.S., the study enrolled 53 patients, with 49 completing the trial, showcasing the feasibility of administering Rolvedon 30 minutes post-chemotherapy, thereby enhancing its clinical applicability.
- Low Adverse Event Rate: Only one patient experienced febrile neutropenia during the trial, with no hospitalizations or antibiotic treatments required, indicating good safety for same-day dosing, which could reduce healthcare costs.
- Future Development Potential: The study results provide crucial data supporting same-day dosing of Rolvedon, potentially leading to broader clinical applications and further solidifying Assertio's market position in oncology treatment.
See More
Assertio Reports Positive Clinical Trial Results for Rolvedon with Same-Day Dosing
- Clinical Trial Success: Assertio's Rolvedon demonstrated similar efficacy and safety in a clinical trial for early-stage breast cancer patients using a same-day dosing schedule, indicating a more convenient treatment option for patients.
- Efficacy Data: Among 53 participants, Rolvedon administered 30 minutes after TC chemotherapy showed a mean time to absolute neutrophil count (ANC) recovery of 1.8 days in Cycle 1, with only one patient experiencing febrile neutropenia, highlighting its strong safety profile.
- Study Impact: This study provides the oncology community with valuable insights into the potential utility of same-day GCSF therapy, which may enhance treatment experiences for early-stage breast cancer patients and reduce infection risks, thereby improving quality of life.
- Market Outlook: Rolvedon is considered a core growth asset for Assertio, and with the release of clinical data, it is expected to drive further penetration and sales growth in the oncology market.
See More
Assertio Holdings declares a 1-for-15 reverse stock split.
Reverse Stock Split Announcement: Assertio Holdings (ASRT) will execute a one-for-fifteen reverse split of its common stock, effective December 26, 2025, at 12:01 a.m. Eastern Time.
Trading Adjustments: The company's common stock will begin trading on a split-adjusted basis when the market opens on the same day, December 26, 2025.
See More
Assertio Holdings to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Assertio Holdings will announce its fourth quarter and full year 2025 financial results on March 16, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Live Webcast Conference: Following the earnings release, management will host a live webcast of the earnings call at 4:30 p.m. Eastern Time, providing investors with a direct opportunity to engage with management and enhance investor confidence.
- Access Information: Investors can visit Assertio's investor relations website to access the live webcast, conference call details, and other materials, ensuring they connect at least 10 minutes prior to the call for any necessary software downloads.
- Telephone Access Option: For those wishing to join by phone only, investors can dial +1 (646) 307-1963 and use call ID 3278948, ensuring flexibility in participation methods to meet investor needs.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Assertio Holdings Regains Nasdaq Compliance with Minimum Bid Price Rule
- Compliance Regained: Assertio Holdings announced that as of January 12, 2026, it has successfully regained compliance with Nasdaq listing requirements by maintaining a minimum bid price of $1.00 per share for ten consecutive days, marking a significant achievement in capital allocation flexibility.
- Successful Reverse Split: The company effectively increased its stock price through a reverse stock split completed in December 2025, ensuring compliance restoration efficiently, which not only boosts market confidence but also provides greater flexibility for future capital operations.
- CEO Statement: CEO Mark Reisenauer expressed satisfaction with the regained compliance, emphasizing that this achievement lays a foundation for the company's future growth and demonstrates Assertio's ongoing competitiveness in the pharmaceutical market.
- Company Background: Assertio is a pharmaceutical company focused on oncology, neurology, and pain management, dedicated to offering differentiated products designed to meet patient needs, and will continue to drive innovation to support patient health.
See More
Assertio Reports Positive Results for Same-Day Dosing of Rolvedon in Clinical Trial
- Clinical Trial Success: Assertio's Rolvedon demonstrated efficacy and safety comparable to next-day dosing in a clinical trial, indicating its potential for improving patient treatment experiences in early-stage breast cancer.
- Patient Participation: Conducted across 13 sites in the U.S., the study enrolled 53 patients, with 49 completing the trial, showcasing the feasibility of administering Rolvedon 30 minutes post-chemotherapy, thereby enhancing its clinical applicability.
- Low Adverse Event Rate: Only one patient experienced febrile neutropenia during the trial, with no hospitalizations or antibiotic treatments required, indicating good safety for same-day dosing, which could reduce healthcare costs.
- Future Development Potential: The study results provide crucial data supporting same-day dosing of Rolvedon, potentially leading to broader clinical applications and further solidifying Assertio's market position in oncology treatment.
See More
Assertio Reports Positive Clinical Trial Results for Rolvedon with Same-Day Dosing
- Clinical Trial Success: Assertio's Rolvedon demonstrated similar efficacy and safety in a clinical trial for early-stage breast cancer patients using a same-day dosing schedule, indicating a more convenient treatment option for patients.
- Efficacy Data: Among 53 participants, Rolvedon administered 30 minutes after TC chemotherapy showed a mean time to absolute neutrophil count (ANC) recovery of 1.8 days in Cycle 1, with only one patient experiencing febrile neutropenia, highlighting its strong safety profile.
- Study Impact: This study provides the oncology community with valuable insights into the potential utility of same-day GCSF therapy, which may enhance treatment experiences for early-stage breast cancer patients and reduce infection risks, thereby improving quality of life.
- Market Outlook: Rolvedon is considered a core growth asset for Assertio, and with the release of clinical data, it is expected to drive further penetration and sales growth in the oncology market.
See More
Assertio Holdings declares a 1-for-15 reverse stock split.
Reverse Stock Split Announcement: Assertio Holdings (ASRT) will execute a one-for-fifteen reverse split of its common stock, effective December 26, 2025, at 12:01 a.m. Eastern Time.
Trading Adjustments: The company's common stock will begin trading on a split-adjusted basis when the market opens on the same day, December 26, 2025.
See More
